New CSF Biomarkers for Alzheimer's Disease

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Aug 3, 2018

Keywords

ClinConnect Summary

This clinical trial is exploring new ways to improve the diagnosis of Alzheimer’s disease (AD) by studying special proteins found in the fluid that surrounds the brain and spinal cord, known as cerebrospinal fluid (CSF). Currently, diagnosing Alzheimer’s often requires complex tests, including a procedure called a lumbar puncture, where a small amount of this fluid is collected. The goal of this study is to collect and store these samples to better understand new biomarkers—substances that could help doctors diagnose and track Alzheimer’s and other types of dementia more effectively.

To participate in this trial, individuals must have had a lumbar puncture done as part of their usual care for dementia. It’s important to note that participants must also give their consent to be part of the study. If eligible, participants will have their CSF samples analyzed for these new biomarkers, which could ultimately lead to improvements in how Alzheimer’s is diagnosed and treated. The trial is open to individuals of all ages and genders who meet the criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Lumbar punction collected in usual practice in the context of dementia diagnosis
• Exclusion Criteria:
• • Absence of consent